Your browser doesn't support javascript.
loading
Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study.
Bar-Or, Amit; Wiendl, Heinz; Montalban, Xavier; Alvarez, Enrique; Davydovskaya, Maria; Delgado, Silvia R; Evdoshenko, Evgeniy P; Giedraitiene, Natasa; Gross-Paju, Katrin; Haldre, Sulev; Herrman, Craig E; Izquierdo, Guillermo; Karelis, Guntis; Leutmezer, Fritz; Mares, Miroslav; Meca-Lallana, Jose E; Mickeviciene, Dalia; Nicholas, Jacqueline; Robertson, Derrick S; Sazonov, Denis V; Sharlin, Kenneth; Sundaram, Bharathy; Totolyan, Natalia; Vachova, Marta; Valis, Martin; Bagger, Morten; Häring, Dieter A; Ludwig, Inga; Willi, Roman; Zalesak, Martin; Su, Wendy; Merschhemke, Martin; Fox, Edward J.
Afiliação
  • Bar-Or A; A Bar-Or Center for Neuroinflammation and Experimental Therapeutics and Department of Neurology, Perelman School of Medicine, University of Pennsylvania, 3400 Spruce Street - 3 Gates Building, Philadelphia, PA 19104, USA.
  • Wiendl H; Center for Neuroinflammation and Experimental Therapeutics and Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Montalban X; Department of Neurology with Institute of Translational Neurology, University of Münster, Münster, Germany.
  • Alvarez E; Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d'Hebron, Barcelona, Spain.
  • Davydovskaya M; Department of Neurology, Rocky Mountain MS Center, University of Colorado, Aurora, CO, USA.
  • Delgado SR; Pirogov Russian National Research Medical University, Moscow, Russian Federation.
  • Evdoshenko EP; MS Center and Department of Neurology, Miller School of Medicine, University of Miami, Miami, FL, USA.
  • Giedraitiene N; St Petersburg Center for Multiple Sclerosis and Other Autoimmune Diseases, St Petersburg, Russian Federation.
  • Gross-Paju K; Clinic of Neurology and Neurosurgery, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Vilnius, Lithuania.
  • Haldre S; West-Tallinn Central Hospital, Tallinn, Estonia/Institute of Health Care Technology, TalTech, Tallinn, Estonia.
  • Herrman CE; Department of Neurology and Neurosurgery, University of Tartu, Tartu, Estonia/Neurology Clinic, Tartu University Hospital, Tartu, Estonia.
  • Izquierdo G; JWM Neurology, Indianapolis, IN, USA.
  • Karelis G; Multiple Sclerosis Unit, Hospital Vithas NISA Sevilla, Sevilla, Spain.
  • Leutmezer F; Neurology and Neurosurgery Department, Riga East University Hospital and Riga Stradins University, Riga, Latvia.
  • Mares M; Department of Neurology, Medical University of Vienna, Vienna, Austria.
  • Meca-Lallana JE; Department of Neurology, Pardubice Regional Hospital, Pardubice, Czech Republic.
  • Mickeviciene D; Multiple Sclerosis CSUR, Department of Neurology, Virgen de la Arrixaca Clinical University Hospital-IMIB-Arrixaca, Murcia, Spain/Clinical Neuroimmunology and Multiple Sclerosis Cathedra, Universidad Católica San Antonio (UCAM), Murcia, Spain.
  • Nicholas J; Lithuanian University of Health Sciences, Kaunas, Lithuania.
  • Robertson DS; OhioHealth Riverside Methodist Hospital, Columbus, OH, USA.
  • Sazonov DV; Multiple Sclerosis Division, Department of Neurology, Morsani College of Medicine, University of South Florida, Tampa, FL, USA.
  • Sharlin K; Department of Clinical Trials FSBIH SDMC of FMBA of Russia, Novosibirsk, Russian Federation.
  • Sundaram B; Sharlin Health and Neurology, Ozark, MO, USA.
  • Totolyan N; Texas Institute for Neurological Disorders, Sherman, TX, USA.
  • Vachova M; Department of Neurology, First Pavlov State Medical University of St Petersburg, St Petersburg, Russian Federation.
  • Valis M; Department of Neurology, Teplice Hospital, Teplice, Czech Republic.
  • Bagger M; Department of Neurology, Faculty of Medicine in Hradec Králové, Charles University in Prague and University Hospital Hradec Králové, Hradec Králové, Czech Republic.
  • Häring DA; Novartis Pharma AG, Basel, Switzerland.
  • Ludwig I; Novartis Pharma AG, Basel, Switzerland.
  • Willi R; Novartis Pharma AG, Basel, Switzerland.
  • Zalesak M; Novartis Pharma AG, Basel, Switzerland.
  • Su W; Novartis Pharma AG, Basel, Switzerland.
  • Merschhemke M; Novartis Pharmaceutical Corporation, East Hanover, NJ, USA.
  • Fox EJ; Novartis Pharma AG, Basel, Switzerland.
Mult Scler ; 28(6): 910-924, 2022 05.
Article em En | MEDLINE | ID: mdl-34605319
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Esclerose Múltipla Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Humans Idioma: En Revista: Mult Scler Assunto da revista: NEUROLOGIA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Esclerose Múltipla Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Humans Idioma: En Revista: Mult Scler Assunto da revista: NEUROLOGIA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos